A novel immune-related prognostic signature in epithelial ovarian carcinoma

Aging (Albany NY). 2021 Apr 4;13(7):10289-10311. doi: 10.18632/aging.202792. Epub 2021 Apr 4.

Abstract

The immune response is associated with the progression and prognosis of epithelial ovarian cancer (EOC). However, the roles of infiltrated immune cells and immune-related genes (IRGs) in EOC have not been reported comprehensively. In the current study, the differentially expressed genes (DEGs) were filtered based on the integrated gene expression data acquired from The University of California at Santa Cruz (UCSC) Genome Browser. Then, IRGs and transcriptional factors (TFs) were screened based on the ImmPort database and Cistrome database. A total of 501 differentially expressed IRGs, and 76 TFs were detected. A TF-mediated network was constructed by univariate Cox analysis to reveal the potential regulatory mechanisms of IRGs. Next, a nine immune-based prognostic risk model using nine IRGs (PI3, CXCL10, CXCL11, LCN6, CCL17, CCL25, MIF, CX3CR1, and CSPG5) was established. Based on the risk score worked out from the signature, the EOC patients could be classified into low-risk and high-risk groups. Furthermore, the immune landscapes, elevated by the cell-type identification by estimating relative subsets of RNA transcripts (CIBERSORT) algorithm and the Tumor Immune Estimation Resource (TIMER) database, effectuated different patterns in two groups. Thus, an immune-based prognostic risk model of EOC elucidates the immune status in the tumor microenvironment, and hence, could be used for prognosis.

Keywords: epithelial ovarian carcinoma; immune; microenvironment; prognostic signature.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Biomarkers, Tumor / immunology
  • Carcinoma, Ovarian Epithelial / immunology*
  • Carcinoma, Ovarian Epithelial / mortality
  • Female
  • Humans
  • Ovarian Neoplasms / immunology*
  • Ovarian Neoplasms / mortality
  • Prognosis
  • Tumor Microenvironment / immunology*

Substances

  • Biomarkers, Tumor